Researchers at the Institut für Experimentelle Immunologie und Bildgebung, University of Essen/Duisberg, have discovered a major finding that may in the future provide a simple way for oncologists to monitor the progression of Myelodysplastic Syndromes (MDS) disease. Today, patients suspected of having MDS undergo a series of bone marrow analysis assays. Due to the invasiveness of this procedure, it is not used to monitor the patient's progress on a regular basis. But Prof Matthias Gunzer has shown that with a simple assay based on peripheral blood it may be possible to provide accurate (sometimes more accurate than existing bone marrow assays) assessments of the patients' risk. MetaVi Labs provided the first ever system that can accurately and reliably measure the extracted lymphocyte cell motility of these patients.
The MetaVi Labs Automated Cellular Analysis System (ACAS) was used to test thousands of blood tissue samples in Prof. Gunzer's lab over the past four years. The ACAS system is also capable of scaling to handle the thousands of samples per day that would be required for a clinically viable assay. Purified human neutrophils were stimulated with fMLP [10 nM], CXCL1 [100 ng/ml] and CXCL8 [100 ng/ml]. PBS was used as control.
In the left column, raw videos are shown, the right column contains the same videos tracked via MetaVi's ACAS® software. Yellow circles and blue crosses point to the positions of the cells. Red lines highlight the cell tracks. The results are representative for the HeinzNixdorf-recall control individuals. The video is presented at a frame rate of 30 pics/sec. The video was acquired at 1 pic/8 sec for a total duration of 1 hour.